J3375Inj vancomycin (xellia) 10mg
Published CMS Medicare Part B payment-limit context for J3375, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.142
per 10 MG · Medicare Part B
Down 12.3%from $0.162 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.1659$0.1301
2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: $0.134; 2025-Q4: $0.139; 2026-Q1: $0.134; 2026-Q2: $0.162; 2026-Q3: $0.142
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Vancomycin ingredient family (FDA data as of August 20, 2026).
Tyzavan
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Vancomycin presentations
3 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J3373 | Inj, vancomycin hcl, 10 mg | $0.033 per 10 MG | $0.03 per 10 MG | Up 10.0% | ||
| J3374 | Inj, vancomycin (mylan) 10mg | $0.097 per 10 MG | $0.098 per 10 MG | Down 1.0% | ||
| J3376 | Inj vancomycin (hikma) 10mg | $0.017 per 10 MG | $0.014 per 10 MG | Up 21.4% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.